AZD2811 + Durvalumab for Small Cell Lung Cancer

(TAZMAN Trial)

Recruiting at25 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: AstraZeneca

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial tests a combination of two drugs, AZD2811 and Durvalumab, to maintain cancer control in adults with advanced small-cell lung cancer who responded well to earlier treatment. AZD2811 stops cancer cell growth, and Durvalumab helps the immune system fight the cancer. Durvalumab has shown survival benefits in various cancers, including non-small cell lung cancer.

Research Team

Eligibility Criteria

This trial is for adults with extensive stage small-cell lung cancer (ES-SCLC) who are fit to receive platinum-based chemotherapy and Durvalumab as a first treatment. They should have a life expectancy of at least 12 weeks, be in good physical condition (ECOG 0 or 1), and not have had immune therapy before. People with prior chest radiation, active infections like TB or hepatitis, autoimmune diseases, uncontrolled illnesses, or certain paraneoplastic syndromes can't join.

Inclusion Criteria

Life expectancy ≥12 weeks at Day 1.

I am fully active or restricted in physically strenuous activity but can do light work.

I have never received immune therapy.

Exclusion Criteria

I have had or will have chest radiation before or after systemic therapy.

I do not have active infections like TB, HIV, or hepatitis.

I have or had an autoimmune or inflammatory disorder.

Treatment Details

Interventions

• AZD2811 (Other)
• Carboplatin (Chemotherapy)
• Cisplatin (Chemotherapy)
• Durvalumab (Checkpoint Inhibitor)
• Etoposide (Chemotherapy)

Trial Overview The study tests AZD2811 combined with Durvalumab as maintenance therapy after initial treatment with platinum-based chemo plus Durvalumab for ES-SCLC. It's an open-label Phase II trial where all participants receive the same experimental drugs to assess their effectiveness and safety.

Participant Groups

Group I: AZD2811 + Durvalumab Experimental Treatment 5 Interventions

Induction: Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin \& Etoposide) Maintenance: AZD2811 + Durvalumab

Carboplatin is already approved in Canada for the following indications:

Approved in Canada as Carboplatin for:

• Ovarian cancer
• Small cell lung cancer
• Testicular cancer

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials

4,491

Recruited

290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology